Evidence map›Paper›PMID 40136706›Full record

ReviewCells2025

A Comprehensive Exploration of the Biological Effects of Adipose-Derived Stem Cells in the Treatment of Systemic Sclerosis.

Gabriele Storti, Riccardo Foti, Roberta Foti, Marco Palmesano, Martina Patacchiola, Dalila Incognito, Giulio Cervelli, Benedetto Longo, Maria Giovanna Scioli, Elena Fiorelli and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Gabriele StortiPlastic Surgery, Department of Surgical Sciences, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0001-7147-9854
Riccardo FotiPlastic Surgery, Department of Surgical Sciences, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0009-0003-9549-7952
Roberta FotiDivision of Rheumatology, A.O.U. "Policlinico-San Marco", 95123 Catania, Italy.ORCID 0000-0002-3074-4508
Marco PalmesanoPlastic Surgery, Department of Surgical Sciences, University of Rome "Tor Vergata", 00133 Rome, Italy.
Martina PatacchiolaPlastic Surgery, Department of Surgical Sciences, University of Rome "Tor Vergata", 00133 Rome, Italy.
Dalila IncognitoMedical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.ORCID 0000-0002-8943-2963
Giulio CervelliDepartment of Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
Benedetto LongoPlastic Surgery, Department of Surgical Sciences, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0001-8671-0609
Maria Giovanna ScioliAnatomy Pathology Institute, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0002-8458-4108
Elena FiorelliAnatomy Pathology Institute, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.
Sonia TerriacaAnatomy Pathology Institute, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.
Andrea LisaPhD Program in Applied Medical Surgical Sciences, Department of Surgical Sciences, University of Rome "Tor Vergata", Viale Oxford 81, 00133 Rome, Italy.ORCID 0000-0003-2134-5633
Bong Sung KimDepartment of Plastic Surgery and Hand Surgery, University Hospital Zurich, 8006 Zurich, Switzerland.
Augusto OrlandiAnatomy Pathology Institute, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0001-7202-5854
Valerio CervelliPlastic Surgery, Department of Surgical Sciences, University of Rome "Tor Vergata", 00133 Rome, Italy.

Funding

University of Rome Tor Vergata Research Grant of the University of Roma Tor Vergata.
6 · The paper itself

Abstract

Systemic sclerosis (SSc) is a complex autoimmune disease characterized by vasculopathy and tissue fibrosis affecting the skin and internal organs. Genetic and environmental factors influence susceptibility, severity, and onset. Current treatments are limited and not always effective, leading researchers to investigate new approaches, such as the use of adipose-derived mesenchymal stem cells (ADSCs) through fat grafting. This review seeks to understand how ADSCs may impact the development and progression of SSc, with a particular focus on how these cells could alter immune responses and reduce fibrosis. ADSCs have been found to affect various immune cells, including T cells, B cells, macrophages, and dendritic cells, by releasing cytokines, chemokines, and growth factors. These interactions generally suppress inflammation and promote a regulatory immune environment. Additionally, ADSCs can influence the extracellular matrix, helping to prevent fibrosis through signaling molecules like exosomes. ADSCs show promise as a treatment for SSc due to their ability to modulate the immune system and reduce fibrosis. Early clinical studies are encouraging, but more research is needed to fully understand how they work and to develop effective treatment protocols.

Indexed as

Adipose TissueMesenchymal Stem CellsMesenchymal Stem Cell TransplantationScleroderma, SystemicAnimalsFibrosisHumansADSClipofillingsystemic sclerosis

Identifiers

PMID40136706
PMCPMC11941144

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.